User:Mr. Ibrahem/Sacubitril/valsartan

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Sacubitril/valsartan
Sacubitril/valsartan
Combination of
SacubitrilNeprilysin inhibitor
ValsartanAngiotensin II receptor antagonist
Clinical data
Trade namesEntresto, Azmarda, Neparvis, others
Other namesLCZ696
AHFS/Drugs.comMonograph
MedlinePlusa615039
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classAngiotensin receptor-neprilysin inhibitor (ARNi)[2]
Legal status
Legal status
Chemical and physical data
FormulaC96H120N12Na6O21
Molar mass1916.018 g·mol−1
3D model (JSmol)
  • CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
  • InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1
  • Key:ZASXKEGREHRXDL-CAWNUZPDSA-H

Sacubitril/valsartan, sold under the brand name Entresto among others, is a combination medication used for heart failure with reduced ejection fraction.[7] It may be used to replace an ACE inhibitor or an angiotensin receptor blocker.[7] It is taken by mouth.[7]

Common side effects include low blood pressure, cough, kidney problems, and high potassium.[2] Other side effects may include angioedema.[2] Use in pregnancy may harm the baby.[2] It contains sacubitril, a neprilysin inhibitor, and valsartan, a angiotensin receptor blocker.[2] The combination is sometimes known as an "angiotensin receptor-neprilysin inhibitor" (ARNi).[2]

Sacubitril/valsartan was approved for medical use in the United States and Europe in 2015.[5][2] It was approved in Australia in 2016.[1] In the United States it costs about 575 USD per month as of 2021.[9] This amount in the United Kingdom costs the NHS about £92.[7]

References[edit]

  1. ^ a b c "Entresto 24/26 tablets, Entresto 49/51 tablets, Entresto 97/103 tablets (sacubitril/valsartan) Product Information". Therapeutic Goods Administration (TGA). Novartis. Archived from the original on 11 November 2020. Retrieved 21 September 2020.
  2. ^ a b c d e f g h "Sacubitril and Valsartan Monograph for Professionals". Drugs.com. Archived from the original on 4 January 2020. Retrieved 9 October 2021.
  3. ^ "Entresto 24 mg/26 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 24 January 2021. Retrieved 21 September 2020.
  4. ^ "Entresto- sacubitril and valsartan tablet, film coated". DailyMed. 14 June 2020. Archived from the original on 19 April 2020. Retrieved 21 September 2020.
  5. ^ a b "Entresto EPAR". European Medicines Agency (EMA). Archived from the original on 27 February 2021. Retrieved 21 September 2020.
  6. ^ "Neparvis EPAR". European Medicines Agency (EMA). Archived from the original on 28 December 2020. Retrieved 23 September 2020.
  7. ^ a b c d e BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 207. ISBN 978-0-85711-369-6.
  8. ^ "Sacubitril / valsartan (Entresto) Use During Pregnancy". Drugs.com. 20 November 2019. Archived from the original on 17 April 2021. Retrieved 21 September 2020.
  9. ^ "Entresto Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 9 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Sacubitril/valsartan&oldid=1149723183"